Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Binge-Eating Disorder
Conditions
Binge-Eating Disorder
Trial Timeline
Apr 26, 2024 → Dec 1, 2025
NCT ID
NCT06413433About Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo
Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Binge-Eating Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06413433. Target conditions include Binge-Eating Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06568367 | Phase 3 | Recruiting |
| NCT06413433 | Phase 3 | Recruiting |
| NCT05972044 | Phase 3 | Completed |
Competing Products
3 competing products in Binge-Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |